NCT01150812View on ClinicalTrials.gov

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

PHASE1TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Thrombin Inhibition

Interventions

DRUG

AZD8165

Oral suspension, 2 mg/mL and 20 mg/mL, single doses

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY